Voss, M. H., Hierro, C., Heist, R. S., Cleary, J. M., Meric-Bernstam, F., Tabernero, J., . . . Baselga, J. (2019). A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical cancer research, 25(9), 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959
Citace podle Chicago (17th ed.)Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research 25, no. 9 (2019): 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959.
Citace podle MLA (9th ed.)Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research, vol. 25, no. 9, 2019, p. 2699, https://doi.org/10.1158/1078-0432.CCR-18-1959.